Shenzhen Xiongshengwei Technology Co., Ltd. – Trademark Portfolio

Entity Type: 16

Shenzhen Xiongshengwei Technology Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include BALIME. The owner is based in Shenzhen.

Tairan 6th Road, Shatou Street, Futian Dist

2C-218Q, 2Fl, Bldg 213, Tairan Technology Park

Shenzhen 518000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

BALIME
BALIME
Registered 2025

Trademark Classifications

Shenzhen Xiongshengwei Technology Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Shenzhen Xiongshengwei Technology Co., Ltd. have?

Shenzhen Xiongshengwei Technology Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Shenzhen Xiongshengwei Technology Co., Ltd. file in?

Shenzhen Xiongshengwei Technology Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 10 (Medical Apparatus). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Shenzhen Xiongshengwei Technology Co., Ltd.'s most well-known trademarks?

Shenzhen Xiongshengwei Technology Co., Ltd.'s registered trademark portfolio includes well-known marks such as BALIME. These are among 1 currently registered trademark in the portfolio.

What is Shenzhen Xiongshengwei Technology Co., Ltd.'s trademark registration success rate?

Shenzhen Xiongshengwei Technology Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.